Keywords
aciclovir
Herpes virus
Embarazo
Tratamiento
Diagnóstico Genital herpes
Acyclovir
Herpes virus
Pregnancy
Treatment
Diagnosis
How to Cite
Abstract
Genital herpes is a chronic infection characterized by periodic reactivations. It is able a cause both a symptomatic disease in the host and to generate an asymptomatic viral expression. Genital herpes is currently the first cause of ulcerative genital lesions and constitutes a significant health problem leading to considerable clinical, psychological, social and economic consequences. This review is intended as an update on the therapeutic options for this condition in immunoincompetent patients, emphasizing the route of administration, the dosing interval, duration of treatment and time to resolution of the lesions. Moreover, the infection prevention strategies and treatment under particular situations such as pregnancy are analyzed.
References
Carter J, Saunders VA. Herpesviruses (and other dsDNA viruses). In: Virology: Principles and Applications. Wiley; 2007:122-135.
Brugha R, Keersmaekers K, Renton a, Meheus a. Genital herpes infection: a review. Int J Epidemiol. 1997;26(4):698-709. Available at: http:// www.ncbi.nlm.nih.gov/pubmed/9279600. https://doi.org/10.1093/ije/26.4.698
Workowski KA, Berman SM. Sexually Transmitted Diseases Treatment Guidelines. Morb Mortal Wkly Rep. 2006;55:1-94. https://doi.org/10.1037/e528752006-001
Mindel A. Genital herpes--how much of a public-health problem? Lancet. 1998;351 Suppl :16-8. Available at: http://www.ncbi.nlm.nih.gov/ pubmed/9652715. https://doi.org/10.1016/S0140-6736(98)90005-8
Melville J, Sniffen S, Crosby R, et al. Psychosocial impact of serological diagnosis of herpes simplex virus type 2: a qualitative assessment. Sex Transm Infect. 2003;79(4):280-5. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1744709&tool=pmcentrez& rendertype=abstract. https://doi.org/10.1136/sti.79.4.280
Brookes JL, Haywood S, Green J. Adjustment to the psychological and social sequelae of recurrent genital herpes simplex infection. Genitourin Med. 1993;69(5):384-7. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1195124&tool=pmcentrez&rendertype=abstract. https://doi.org/10.1136/sti.69.5.384
Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health. 2000;36(1):11-9. https://doi.org/10.1363/3601104
Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J Acquir Immune Defic Syndr. 2004;35(5):435-45. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15021308. https://doi.org/10.1097/00126334-200404150-00001
Azwa A, Barton SE. Aspects of herpes simplex virus: a clinical review. J Fam Plann Reprod Health Care. 2009;35(4):237-42. https://doi.org/10.1783/147118909789587376
Drake S, Taylor S, Brown D, Pillay D. Improving the care of patients with genital herpes. BMJ. 1998;321:619-623. https://doi.org/10.1136/bmj.321.7261.619
Carney O, Ross E, Ikkos G, Mindel a. The effect of suppressive oral acyclovir on the psychological morbidity associated with recurrent genital herpes. Genitourin Med. 1993;69(6):457-9. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1195151&tool=pmcent rez&rendertype=abstract. https://doi.org/10.1136/sti.69.6.457
Whitley RJ, Kimberlin DW, Roizman B. Herpes Simplex Viruses. Clin Infect Dis. 1998;26:541-555. https://doi.org/10.1086/514600
Nunes Miranda CA, Galvão Lima E, Soares de Lima DB, et al. Genital infection with herpes simplex virus types 1 and 2 in women from natal, Brazil. ISRN Obstet Gynecol. 2014;2014:323657. https://doi.org/10.1155/2014/323657
Looker K. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ. 2008;86(10):805-812. https://doi.org/10.2471/BLT.07.046128
Centers for Disease Control and Prevention. Incidence, Prevalence, and Cost of Sexually Transmitted Infections in the United States. CDC Fact Sheet. 2013:1-4. Available at: http://www.cdc.gov/std/stats/sti-estimates-fact-sheet-feb-2013.pdf. Accessed June 16, 2014.
Xu F, Sternberg MR, Gottlieb S, et al. Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. MMWR Morb Mortal Wkly Rep. 2010;59(15):456-9. Available at: http://www.ncbi.nlm.nih.gov/pubmed/20414188.
Clemens SAC, Farhat CK. Seroprevalence of herpes simplex 1-2 antibodies in Brazil. Rev Saude Publica. 2010;44(4):726-34. Available at: http://https://doi.org/10.1590/S0034-89102010000400017 www.ncbi.nlm.nih.gov/pubmed/20676563.
Barnabas R V, Celum C. Infectious Co-factors in HIV-1 transmission Herpes Simplex Virus type-2 and HIV-1: New Insights and interventions. Curr HIV Res. 2013;10(3):228-237. https://doi.org/10.2174/157016212800618156
Ministerio de Salud y Protección Social. Situación de las infecciones de transmisión sexual diferentes al VIH. Colombia 2009-2011; 2011.
Koutsky LA, Ashley RL, Holmes KK, et al. Frequency Unrecognized Type 2 Herpes Simplex Virus Infection Among Women. Sex Transm Dis. 1990;17(2):90-94. https://doi.org/10.1097/00007435-199004000-00009
Schiffer JT, Corey L. Rapid host immune response and viral dynamics in herpes virus-2 infection. Nat Med. 2013;19(3):280-290. https://doi.org/10.1038/nm.3103
Wald A, Zeh J, Selke S, Ashley RL, Corey L. Virologic characteristics of subclinical and symptomatic genital herpes infections. N Engl J Med. 1995;333:770-775. https://doi.org/10.1056/NEJM199509213331205
Wald A, Zeh J, Selke S, et al. Reactivation of Genital Herpes Simplex Virus Type 2 Infection In Asymptomatic Seropositive Persons. N Engl J Med. 2000;342:844-50. https://doi.org/10.1056/NEJM200003233421203
Schacker T, Ryncarz a J, Goddard J, Diem K, Shaughnessy M, Corey L. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA. 1998;280(1):61-6. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9660365. https://doi.org/10.1001/jama.280.1.61
Beauman JG. Genital herpes: a review. Am Fam Physician. 2005;72(8):1527-34. Available at: http://www.ncbi.nlm.nih.gov/pubmed/22498948.
Stewart J a, Reef SE, Pellett PE, Corey L, Whitley RJ. Herpesvirus infections in persons infected with human immunodeficiency virus. Clin Infect Dis. 1995;21 Suppl 1:S114-20. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8547499. https://doi.org/10.1093/clinids/21.Supplement_1.S114
Efstathiou S, Preston CM. Towards an understanding of the molecular basis of herpes simplex virus latency. Virus Res. 2005;111(2):108-19. https://doi.org/10.1016/j.virusres.2005.04.017
Farley N, Bernstein DI, Bravo FJ, Earwood J, Sawtell N, Cardin RD. Recurrent vaginal shedding of herpes simplex type 2 virus in the mouse and effects of antiviral therapy. Antiviral Res. 2010;86(2):188-195. https://doi.org/10.1016/j.antiviral.2010.02.317
Corey L. First-episode, recurrent, and asymptomatic herpes simplex infections. J Am Acad Dermatol. 1988;18(1 Pt 2):169-72. https://doi.org/10.1016/S0190-9622(88)70020-1
Kinghorn GR. Epidemiology of genital herpes. J Int Med Res. 1994;22 Suppl 1:14A-23A.
Chentoufi AA, Dervillez X, Rubbo P, et al. Current trends in negative immuno-synergy between two sexually transmitted infectious viruses: HIV-1 and HSV-1/2. Curr Trend Immunol. 2012;13:51-68.
Benedetti JK, Corey L, Ashley RL. Recurrence Rates in Genital Herpes after symptomatic First-Episode Infection. Ann Intern Med. 1994;121:847-854. https://doi.org/10.7326/0003-4819-121-11-199412010-00004
Corey L. The current trend in genital herpes. Progress in prevention. Sex Transm Dis. 1994;21(2 Suppl):S38-44.
Workowski KA, Berman S. Sexually Transmitted Diseases Treatment Guidelines, 2010. Morb Mortal Wkly Rep. 2010;59(RR-12).
Abudalu M, Tyring S, Koltun W, Bodsworth N, Hamed K. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes: a randomized, double-blind, comparative trial. Clin Infect Dis. 2008;47(5):651-8. https://doi.org/10.1086/590561
Mostow SR, Mayfield JL, Marr JJ, Drucker JL. Supression of recurrent genital herpes by single daily dosages of acyclovir. Am J Med. 1988;85(2A):30-3.
Sacks SL. Patient-Initiated, Twice-Daily Oral Famciclovir for Early Recurrent Genital Herpes. JAMA. 1996;276(1):44.
https://doi.org/10.1001/jama.1996.03540010046029
Wald A, Ashley-Morrow R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin Infect Dis. 2002;35(Suppl 2):S173-82. https://doi.org/10.1086/342104
Sen P, Barton SE. Genital herpes and its management. BMJ. 2007;334(7602):1048-52. https://doi.org/10.1136/bmj.39189.504306.55
Modi S, Van L, Gewirtzman A, et al. Single-day treatment for orolabial and genital herpes: a brief review of pathogenesis and pharmacology. Ther Clin Risk Manag. 2008;4(2):409-17. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2504076&tool=pmcentrez&rendertype=abstract. https://doi.org/10.2147/TCRM.S1664
Mindel A, Adler MW, Sutherland S, Fiddian AP. Intravenous Acyclovir Treatment for Primary Genital Herpes. Lancet. 1982;1(8274):697-700. https://doi.org/10.1016/S0140-6736(82)92618-6
Lebrun-Vignes B, Bouzamondo A, Dupuy A, Guillaume J-C, Lechat P, Chosidow O. A meta-analysis to assess the efficacy of oral antiviral treatment to prevent genital herpes outbreaks. J Am Acad Dermatol. 2007;57(2):238-46. https://doi.org/10.1016/j.jaad.2007.02.008
Simpson D, Lyseng-Williamson KA. Famciclovir. A Review of its Use in Herpes Zoster and Genital and Orolabial Herpes. Drugs. 2006;66(18):2397-2416. https://doi.org/10.2165/00003495-200666180-00016
MacDougall C, Guglielmo BJ. Pharmacokinetics of valaciclovir. J Antimicrob Chemother. 2004;53(6):899-901. https://doi.org/10.1093/jac/dkh244
De Clercq E. Antiviral drugs: current state of the art. J Clin Virol. 2001;22(1):73-89. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11418355. https://doi.org/10.1016/S1386-6532(01)00167-6
International Agency for Research on Cancer. Acyclovir. IARC Monogr Eval Carcinog Risks to Humans. 2000;76:47-71. Available at: http://monographs.iarc.fr/ENG/Monographs/vol76/mono76-6.pdf.
Chono K, Katsumata K, Kontani T, et al. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2. J Antimicrob Chemother. 2010;65(8):1733-41. https://doi.org/10.1093/jac/dkq198
Tyring S, Wald A, Zadeikis N, Dhadda S, Takenouchi K, Rorig R. ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study. J Infect Dis. 2012;205(7):1100-10. https://doi.org/10.1093/infdis/jis019
Martín JM, Villalón G, Jordá E. Update on the Treatment of Genital Herpes. Actas Dermo-Sifiliográficas (English Ed. 2009;100(1):22-32. https://doi.org/10.1016/S1578-2190(09)70006-X S1578-2190(09)70006-X.
Phase III Study of ASP2151 in Herpes Simplex Patients. Available at: http://clinicaltrials.gov/show/NCT01959295.
Chono K, Katsumata K, Suzuki H, Shiraki K. Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus. Antiviral Res. 2013;97(2):154-160. https://doi.org/10.1016/j.antiviral.2012.12.006
Corey L, Wald A, Patel R, et al. Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes. N Engl J Med. 2004;350(1):11-20. https://doi.org/10.1056/NEJMoa035144
Bavaro JB, Drolette L, Koelle DM, et al. One-day regimen of valacyclovir for treatment of recurrent genital herpes simplex virus 2 infection. Sex Transm Dis. 2008;35(4):383-6. https://doi.org/10.1097/OLQ.0b013e31815e4190
Wald A, Carrell D, Remington M, Kexel E, Zeh J, Corey L. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection. Clin Infect Dis. 2002;34(7):944-8. https://doi.org/10.1086/339325
Aoki FY, Tyring S, Diaz-mitoma F, Gross G, Gao J, Hamed K. Single-Day, Patient-Initiated Famciclovir Therapy for Recurrent Genital Herpes : A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis. 2006;42:8-13. https://doi.org/10.1086/498521
Chentoufi AA, Kritzer E, Yu DM, Nesburn AB, Benmohamed L. Towards a rational design of an asymptomatic clinical herpes vaccine: the old, the new, and the unknown. Clin Dev Immunol. 2012;2012:1-16. https://doi.org/10.1155/2012/187585
Johnston C, Koelle DM, Wald A. HSV-2: in pursuit of a vaccine. J Clin Invest. 2011;121(12):4600-4609. https://doi.org/10.1172/JCI57148
Corey L, Wald A. Maternal and Neonatal HSV Infections. N Engl J Med. 2009;361(14):1376-1385. https://doi.org/10.1056/NEJMra0807633
Straface G, Selmin A, Zanardo V, De Santis M, Ercoli A, Scambia G. Herpes simplex virus infection in pregnancy. Infect Dis Obstet Gynecol. 2012;2012:385697. https://doi.org/10.1155/2012/385697
Brown ZA, Selke S, Zeh J, et al. The Acquisition of Herpes Simplex Virus. N Engl J Med. 1997;337(8):509-515 https://doi.org/10.1056/NEJM199708213370801
Sauerbrei A, Wutzler P. Herpes simplex and varicella-zoster virus infections during pregnancy: current concepts of prevention, diagnosis and therapy. Part 1: herpes simplex virus infections. Med Microbiol Immunol. 2007;196(2):89-94. https://doi.org/10.1007/s00430-006-0031-0
Brown ZA, Gardella C, Wald A, Morrow RA, Corey L. Genital herpes complicating pregnancy. Obstet Gynecol. 2005;106(4):845-56. https://doi.org/10.1097/01
Kimberlin DW, Baley J. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. Pediatrics. 2013;131(2):e635-46. https://doi.org/10.1542/peds.2012-3216
Westhoff GL, Little SE, Caughey AB. Herpes simplex virus and pregnancy: a review of the management of antenatal and peripartum herpes infections. Obstet Gynecol Surv. 2011;66(10):629-38. https://doi.org/10.1097/OGX.0b013e31823983ec
U.S. Department of Health and Human Services, Food and Drug Administration. Reviewer Guidance: Evaluating the Risks of Drug Exposure in Human Pregnancies; 2005:1-31.
Pasternak, B. Hviid A. Use of Acyclovir, Valacyclovir, and Famciclovir in the First Trimester of Pregnancy and the Risk of Birth Defects. JAMA. 2010;304(8):859-66. https://doi.org/10.1001/jama.2010.1206
Aga IE, Hollier LM. Managing genital herpes infections in pregnancy. Womens Health (Lond Engl). 2009;5(2):165-72; quiz 73-4. https://doi.org/10.2217/17455057.5.2.165
Sheffield J. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review. Obstet Gynecol. 2003;102(6):1396-1403. https://doi.org/10.1016/j.obstetgynecol.2003.08.015
Watts DH, Brown Z a., Money D, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol. 2003;188(3):836-843. https://doi.org/10.1067/mob.2003.185
Andrews WW, Kimberlin DF, Whitley R, Cliver S, Ramsey PS, Deeter R. Valacyclovir therapy to reduce recurrent genital herpes in pregnant women. Am J Obstet Gynecol. 2006;194(3):774-81. https://doi.org/10.1016/j.ajog.2005.11.051
Sheffield JS, Hill JB, Hollier LM, et al. Valacyclovir Prophylaxis to Prevent Recurrent Herpes at Delivery. Obstet Gynecol. 2006;108(1):141-147. https://doi.org/10.1097/01.AOG.0000219749.96274.15
Hollier LM, Wendel GD. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus ( HSV ) recurrences and neonatal infection. Cochrane Database Syst Rev. 2008;(1). https://doi.org/10.1002/14651858.CD004946.pub2
Money D, Steben M. Guidelines for the management of herpes simplex virus in pregnancy. Int J Gynecol Obstet. 2008;30(6):514-519. https://doi.org/10.1016/j.ijgo.2008.10.028
Kimberlin DW, Baley J. Guidance on management of asymptomatic neonates born to women with active genital herpes lesions. Pediatrics. 2013;131(2):e635-46. https://doi.org/10.1542/peds.2012-3216
Cleary KL, Paré E, Stamilio D, Macones G a. Type-specific screening for asymptomatic herpes infection in pregnancy: a decision analysis. BJOG. 2005;112(6):731-6. https://doi.org/10.1111/j.1471-0528.2005.00540.x
Tita ATN, Grobman WA, Rouse DJ. Antenatal Herpes Serologic Screening: An Appraisal of the Evidence. Obstet Gynecol. 2006;108(5):1247-1253. https://doi.org/10.1097/01.AOG.0000236433.29679.9a
Brown Z a. Effect of Serologic Status and Cesarean Delivery on Transmission Rates of Herpes Simplex Virus From Mother to Infant. Jama. 2003;289(2):203. https://doi.org/10.1001/jama.289.2.203
Jones C a. Vertical transmission of genital herpes: prevention and treatment options. Drugs. 2009;69(4):421-34. https://doi.org/10.2165/00003495-200969040-00003